Liav Abraham

Endo Wins Citi Upgrade On Positive Catalysts, Cellulite Treatment Opportunity

Why Is Teva Falling? Competition

What Approval For Generic Copaxone Means For Mylan

Why Is Teva Falling? Competition

What Approval For Generic Copaxone Means For Mylan

Citi Weighs In On The 'Turmoil At Teva'

Citi: Buy Horizon Pharma

Citi Weighs In On The 'Turmoil At Teva'

Citi: Buy Horizon Pharma

Citi Downgrades Zoetis, Cites Valuation

Citi Maintains Its Constructive Stance On Allergan

Liav Abraham Recent News

It's Not Over For Teva Just Yet After J-Code Rejection, Citi Says

Is Allergan Worth Over $300 Without Pfizer?

2 Pharma Stocks To Hide In While Drug Pricing Fears Play Out

Citi Asks: Is A Mylan-Perrigo Merger Smart?

And The Winner From The Mylan-Perrigo Merger Is... Teva?

Does Teva Pharmaceutical's New Executive Hint At A Coming M&A Deal?

Citigroup Says Actavis Is Now Worth $360 Per Share (And It's A Buy)

Citigroup Ponders How Results From Namenda Survey Might Affect Actavis

Citigroup Offers Thoughts On Zoetis Ahead Of Investor Day

Citi Raises Price Target On Actavis

UPDATE: Citigroup Initiates Coverage On DBV Technologies As Stock Is Not Fully Appreciated

Analyst: Bill Ackman's Zoetis Move Casts Doubt On Allergan Bid

UPDATE: Citigroup Reiterates On Zoetis Following Pershing Confirmation

Activis Shares Languish Post-Forest Deal

Analysts See Allergan Bid Of Over $180, Possibility of 'Hostile' Bid

Citigroup Slaps $70 Price Target on Teva, Highest on Street

Teva Offers Most Attractive Risk-Reward Profile, Citigroup Says

UPDATE: Allergan Upgraded by Citigroup on Strong Fundamentals

UPDATE: Citigroup Reiterates on Endo Health Solutions on Potential of Paladin Acquisition

UPDATE: Citigroup Initiates Coverage on Actavis PLC as Stock is Firing on All Cylinders

UPDATE: Citigroup Initiates Coverage on Teva Pharmaceutical Industries Ltd. on Attractive Risk-Reward Profile